• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Cyanokit (hydroxocobalamin) intravenous use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2010

Summary View

 

USE IN SPECIFIC POPULATIONS

Pregnancy
  • Based on animal studies, may cause fetal harm; however, treatment of maternal/fetal cyanide poisoning may be lifesaving.
Nursing mothers
  • Because of the unknown potential for adverse reactions in nursing infants, discontinue nursing after Cyanokit treatment